Standards & Regulation

That which we call rosaimab by any other name would find regulatory approval and commercial success. Or would it?

What is going on with Aduhelm? And why is the drug seen by some to be controversial?

An industry consortium is tackling one of pharma’s biggest drug-related challenges.

It’s time for pharma companies to embrace digital technologies.

IFPMA’s Director-General, Thomas Cueni, outlines how companies worldwide can foster long-term tech transfer partnerships.

Companies must adapt to the requirements of rigorous remote inspections.

Welcome to Part II of our roundtable discussion about a pilot program in the US for novel excipients featuring experts from IPEC-Americas.

Read our roundtable discussion about a pilot program in the US for novel excipients featuring experts from IPEC-Americas.

A best practice competition developed to encourage labs to pursue more efficient cold storage is now on for 2022.

How can we overcome red tape and roadblocks to ensure a steady supply of pharmaceutical ingredients?